Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Clinical trial NCT06178211 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06178211
Sponsor: Shanghai Chest Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma

Start date: 2023-12-01
Primary completion: 2025-03-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.